You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Baxter
McKinsey

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,950,039


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,950,039
Title:Insulin glargine/lixisenatide fixed ratio formulation
Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
Inventor(s): Souhami; Elisabeth (Paris, FR), Silvestre; Louise (Paris, FR)
Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:14/965,586
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,950,039

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG   Start Trial
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN   Start Trial
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,950,039

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
14197685Dec 12, 2014
15193940Nov 10, 2015

International Family Members for US Patent 9,950,039

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 102978   Start Trial
Australia 2015359376   Start Trial
Brazil 112017012406   Start Trial
Canada 2970200   Start Trial
Chile 2017001483   Start Trial
China 107206058   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Dow
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.